Unprecedented activity of a once-weekly drug combination

Wednesday, January 07th, 2009 by hinrich

Article by Veziris et al.

Treating tuberculosis patients requires a monitoring of medicine intake to ensure that patients comply with the drug administration requirements. Given the long treatment against Mycobacterium tuberculosis (typically a once-daily for six months), it would be desirable to treat patients once-weekly.

Veziris et al. have now published an article where they describe an unprecedented activity of a once-weekly regimen in a mouse model: Eight once-per-week doses of a triple-drug combination of TMC207/R207910, rifapentine and pyrazinamide resulted in negative lung-cultures in 9 out of 10 mice (Combination therapy is administered to prevent the emergence of resistant bacteria). They also show that the bactericidal activity of TMC207/R207910 alone in the mouse model correlates with the total dose irrespective of the frequency of administration (TMC207/R207910 has a long half-life of approx. 7 days in humans and 2 days in mice).

While the disease shows some differences between the situation in human and in the mouse model, these findings are encouraging and could potentially indicate the possibility of a short-course treatment of tuberculosis.

You can read the paper here.

Posted in Tuberculosis